X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs SANOFI INDIA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS SANOFI INDIA IPCA LABS/
SANOFI INDIA
 
P/E (TTM) x 28.0 37.0 75.5% View Chart
P/BV x 3.6 7.0 50.9% View Chart
Dividend Yield % 0.1 0.5 24.3%  

Financials

 IPCA LABS   SANOFI INDIA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
SANOFI INDIA
Dec-17
IPCA LABS/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs6954,945 14.1%   
Low Rs4003,901 10.3%   
Sales per share (Unadj.) Rs260.21,081.8 24.1%  
Earnings per share (Unadj.) Rs19.0141.6 13.4%  
Cash flow per share (Unadj.) Rs33.1185.9 17.8%  
Dividends per share (Unadj.) Rs1.0033.00 3.0%  
Dividend yield (eoy) %0.20.7 24.5%  
Book value per share (Unadj.) Rs213.0868.8 24.5%  
Shares outstanding (eoy) m126.2023.03 548.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.1 51.5%   
Avg P/E ratio x28.931.2 92.4%  
P/CF ratio (eoy) x16.623.8 69.7%  
Price / Book Value ratio x2.65.1 50.5%  
Dividend payout %5.323.3 22.6%   
Avg Mkt Cap Rs m69,120101,862 67.9%   
No. of employees `00013.33.2 409.2%   
Total wages/salary Rs m7,3593,685 199.7%   
Avg. sales/employee Rs Th2,477.47,691.9 32.2%   
Avg. wages/employee Rs Th555.21,137.7 48.8%   
Avg. net profit/employee Rs Th180.61,006.5 17.9%   
INCOME DATA
Net Sales Rs m32,83624,914 131.8%  
Other income Rs m418807 51.8%   
Total revenues Rs m33,25425,721 129.3%   
Gross profit Rs m4,5055,372 83.9%  
Depreciation Rs m1,7771,022 173.9%   
Interest Rs m24011 2,183.6%   
Profit before tax Rs m2,9055,146 56.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,886 27.1%   
Profit after tax Rs m2,3943,260 73.4%  
Gross profit margin %13.721.6 63.6%  
Effective tax rate %17.636.6 48.0%   
Net profit margin %7.313.1 55.7%  
BALANCE SHEET DATA
Current assets Rs m19,45514,432 134.8%   
Current liabilities Rs m10,0766,010 167.6%   
Net working cap to sales %28.633.8 84.5%  
Current ratio x1.92.4 80.4%  
Inventory Days Days9861 160.8%  
Debtors Days Days6728 235.1%  
Net fixed assets Rs m20,2607,991 253.5%   
Share capital Rs m252230 109.6%   
"Free" reserves Rs m26,63319,778 134.7%   
Net worth Rs m26,88620,008 134.4%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17327,770 148.3%  
Interest coverage x13.1468.8 2.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.9 88.9%   
Return on assets %6.411.8 54.3%  
Return on equity %8.916.3 54.7%  
Return on capital %10.825.8 41.8%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6426,306 248.1%   
Fx outflow Rs m4,8845,257 92.9%   
Net fx Rs m10,7591,049 1,025.6%   
CASH FLOW
From Operations Rs m3,4114,351 78.4%  
From Investments Rs m-1,354-787 172.0%  
From Financial Activity Rs m-1,304-1,884 69.2%  
Net Cashflow Rs m7531,680 44.8%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 11.4 14.4 79.2%  
FIIs % 25.3 14.6 173.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.5 165.7%  
Shareholders   36,892 15,184 243.0%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DR. REDDYS LAB  STERLING BIOTECH  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Nov 16, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS